Brief: Alligator Bioscience, Aptevo Therapeutics Announce Positive Interim Data From Dose Escalation Phase Of Their Phase 1 Trial
16/09/2024 13:12
Sept 16 (Reuters) - Alligator Bioscience AB ATORX.ST
* CO AND APTEVO THERAPEUTICS TODAY ANNOUNCED POSITIVE
INTERIM DATA
FROM DOSE ESCALATION PHASE OF THEIR PHASE 1 TRIAL EVALUATING
ALG.APV-527 FOR TREATMENT OF SOLID TUMORS LIKELY TO EXPRESS
TUMOR ANTIGEN 5T4
Source text for Eikon: ID:nMFN46GfS4
Further company coverage: ATORX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Alligator Bioscience AB
See all newsBrief: Alligator Bioscience Q1 Net Loss SEK 1.4 Million
Sweden's Alligator Bioscience posts Q1 net profit, narrows operating loss
Brief: Alligator Bioscience Q1 EBIT SEK -17.8 Million
Brief: Alligator Bioscience Signs LoI With Unicancer For Phase 3 Mitazalimab Development
Brief: Exercise Of Warrants Brings Alligator Bioscience Net Proceeds Of SEK 12 Mln